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Purpose: Considering the fact that many mistakes are still being made by asthmatic patients when 
inhaling lung medication, it is important to gain insight into current techniques used to administer 
intranasal corticosteroid sprays (INCS) in allergic rhinitis patients. In this study, we aimed to 
get insight into daily use of INCS and to determine if improvement of the technique is required.
Patients and methods: A checklist, based on available patient information leaflets (PILs) 
and literature, was used to determine the participants’ application of the techniques used to 
administer INCS. These applied techniques were compared with steps described in PILs and 
recommended essential steps.
Results: In the overall population (64 participants) four participants (6%) carried out all steps as 
described in the PIL and seven participants (11%) carried out all recommended essential steps.
Conclusion: The technique used to administer INCS is inadequate. Uniform and generally 
applicable instructions are needed and patients using INCS should be guided better.
Keywords: intranasal corticosteroid sprays, allergic rhinitis, administration techniques, quality 
of administration
Introduction
Allergic rhinitis (AR) is a common disease, affecting children, adolescents, and adults. 
The prevalence ranges from 8.5% in children to 27.2% in adults.1–3 Pharmacological 
agents for AR are aimed at preventing and reducing symptoms. Antihistamines and 
corticosteroids are available in oral and intranasal dosage forms. In case of cortico-
steroids, intranasally administered sprays or drops are preferred due to adverse effects 
(AEs) after systemic use.3
Considering the fact that many mistakes are still being made by asthmatic patients 
during inhalation of lung medication, it is important to gain insight into current techniques 
used to administer intranasal corticosteroid sprays (INCS) in AR patients.4 Relatively little 
research has been done about the relation between intranasal administration technique 
and efficacy. The technique of INCS may affect efficacy, adverse events, and compliance.5 
In studies, recommendations are imposed to reach highest efficacy and prevent AEs.6–8
In this descriptive, observational study, we aimed to get insight into the current 
techniques used to administer INCS and to determine if improvement of the technique 
is required.
Material and methods
Participants were selected from the drug surveillance databases of public pharmacies in 
Drachten (The Netherlands). Participation was based on the following inclusion criteria: 
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patients were aged 8–30 years old and had been using INCS 
for a minimum period of 1 week. Patients were excluded 
when they were unable to complete study procedures or did 
not understand and speak the Dutch language fluently. The 
following active compounds were included: beclomethasone, 
budesonide, fluticasone furoate, fluticasone propionate, and 
mometasone furoate, brand name and generic dosage forms 
were included. Eligible patients were approached randomly 
and actively asked if they wanted to participate in the study. 
When patients wanted to participate, the application tech-
nique of the INCS was directly observed in a face-to-face 
interview. The objective of the interview was to gain insight 
into the techniques used to administer INCS. All participants 
were interviewed and observed by the same investigator. The 
administration techniques were scored using a checklist. This 
checklist included all maneuvers for daily administration of 
INCS as indicated in the patient information leaflet (PIL) 
of the spray the participant used. The complete instruction 
for administration of INCS in PILs contained a maximum 
of eleven steps; however for some steps different instruc-
tions were described and not all steps were described in the 
different PILs (Table 1). The recommended essential steps 
were based on available literature (Table 2).6–8 In the analysis, 
descriptive statistics were used and a significant difference 
between populations could not be proved in this study. The 
study protocol was approved by the medical ethics committee 
of Medical Centre Leeuwarden (MCL). All patients and, if 
necessary, their caregivers, gave written informed consent.
Results
We analyzed the application of the recommended maneu-
vers in 64 participants by direct observation of intranasal 
administration (Table 1). Participant characteristics are 
presented in Table 3. Overall, the majority of participants 
were female, used an INCS for AR on a daily basis, got 
prescribed mometasone furoate, and had an average age 
of 18.4 years. Only four participants (6%) carried out all 
steps as described in the PIL. Taking the dust cap off and 
hand positioning were carried out as described in the PIL 
by all participants. Shaking the device, closing the nostril, 
inhaling, and replacing the dust cap were carried out as 
described in the PIL by the majority of the participants 
(91%; 73%; 98%; and 97%, respectively). Approximately 
half of the participants blew their nose (48%), had correct 
spray positioning (45%), and used correct technique for 
exhalation (54%) and cleaning (52%). Head positioning 
was carried out according to the PIL in approximately 10% 
of the participants (13%).
Table 1 Steps in pIL
Steps in PIL Instruction  
carried out,  
n (%)
 1. Shake the spray 58 (91%)
 2. remove the dust cap 64 (100%)
 3. Blow the nose 31 (48%)
 4. Instruction for hand position 64 (100%)
 5. Instruction for closing the nostril*
 •  put the tip of the nozzle into the nostril and 
close the other nostril
 • put the tip of the nozzle into the nostril
47 (73%)
 6. Instruction for head position*
 • Slightly tilt forward
 • No instruction
7 (13%)
 7. Instruction for position of the spray*
 • point the end of the nozzle slightly outwards, 
away from the septum
 • No instruction
10 (45%)
 8. Inhale instruction*
 • Squirt a spray of mist in the nose while  
breathing in
 • No instruction
61 (98%)
 9. exhale instruction*
 • Breathe out through the mouth
 • No instruction
30 (54%)
10. Clean instruction*
 • Wipe the nozzle with a tissue or handkerchief
 • No instruction
29 (52%)
11. replace the dust cap 62 (97%)
Notes: the eleven steps for administration of INCS as described in the pIL, 
available for patients in the Netherlands. In pILs of different working compounds 
and manufacturers, different instructions for the same step are described (indicated 
with *). It is indicated how many participants (n, %) carried out the instruction per 
step.
Abbreviations: PIL, patient information leaflet; INCS, intranasal corticosteroid 
sprays.
Table 2 recommended essential steps
Essential steps Instruction 
carried out, 
n (%)
1. Shake the spray 58 (91%)
2. Blow the nose 31 (48%)
3.  point the end of the nozzle slightly outwards, away 
from the septum
26 (44%)
4. Squirt a spray of mist in the nose while breathing in 63 (98%)
5. Breathe out through the mouth 31 (48%)
Notes: Described are the five recommended essential steps for administration of 
INCS, data from Benninger et al, Jang et al and tay at al.6–8 It is indicated how many 
participants (n, %) carried out the instruction per step.
Abbreviation: INCS, intranasal corticosteroid sprays.
We analyzed the application of the recommended steps 
for daily administration of INCS as described (Table 2). In 
this population seven participants (11%) carried out all the 
recommended essential steps. Shaking the device and inhal-
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and 98%, respectively). Approximately half of the patients 
blew their nose (48%), had correct spray positioning (44%), 
and used correct exhalation technique (48%).
Discussion
We found that most patients did not take their INCS as 
described in the instructions, and they received instructions 
as described in the PIL after the interview. The techniques 
they used were not according to the PILs or the recommended 
essential steps, thereby the quality of administration can be 
denominated as inadequate in most patients.
Although there has been relatively little research about 
the relation between a particular administration technique and 
efficacy, it may be expected that the administration technique 
of INCS may affect efficacy, occurrence of AEs, and compli-
ance.5 Benninger et al tried to find evidence regarding how to 
instruct patients to use INCS.6 No clear evidence was found 
regarding head positioning and spray position, but based 
on findings in their review, recommendations for the use of 
INCS were established. It is recommended to have the head 
in a neutral position when using INCS spray, because when 
the head is tilted back, the intranasal corticosteroid could 
flow into the throat and cause throat irritation and absorption 
in the gastrointestinal tract.6,7 A Cochrane review showed 
an increased risk of occurrence of epistaxis using an INCS 
compared to placebo or no intervention (RR 2.74, 95% CI 
1.88–4.00; 2,508 participants; 13 studies; high quality evi-
dence).9 To prevent epistaxis it is recommended to point the 
nozzle outwards, away from the nasal septum.6 In the study 
Table 3 participant characteristics
 Overall (n=64)
Gender, n (%)  
Male 19 (30%)
Female 45 (70%)
Age (years), range (median) 8–30 (19)
Indication, n (%)  
Allergic rhinitis 40 (63%)
Inflammation of nasal mucosa 5 (8%)
Nasal polyp 1 (2%)
othera 18 (28%)
Active compound, n (%)  
Mometasone furoate 26 (41%)
Fluticasone propionate 16 (25%)
Fluticasone furoate 14 (22%)
Beclometasone 6 (9%)
Budesonide 2 (3%)
Notes: aother indications, as given by the participants, included cold complaints, 
asthma, and keeping the acoustic duct open.
of Ganesh et al, applying INCS with the ipsilateral hand tech-
nique (for example right hand to right nostril) was compared 
with the contralateral hand technique (for example right hand 
to left nostril) and these data suggest that the contralateral 
technique affects AEs and patient compliance in a positive 
way.5 Based on in vitro computational fluid dynamics, Jang et 
al evaluated the effect of nasal inspiratory airflow on the dis-
tribution of intranasal corticosteroids. They found that using 
a simultaneously gentle inspiration technique improved the 
distribution of intranasal corticosteroids in the nasal cavity 
and that there was better distribution beyond the nasal valve. 
Sniffing too hard can result in additional turbulence gener-
ated in the nasal cavity and thereby deposition in the throat.8
Although less thorough research has been done about 
the best application technique, these recommendations can 
lead to a structural, standardized protocol for administration 
of INCS.
Our data indicate that many steps for administration of 
INCS are skipped or not executed. An explanation for this 
could be that patients are not fully aware of the existence 
of a comprehensive set of instructions for administering 
INCS in PILs. Other reasons for not carrying out all steps 
of administration can be sloppiness, forgetting how to do it 
or unclear instructions given by doctor or pharmacist. It is 
unclear now how patients determine how to use their INCS. 
Patients using INCS should be better informed about the 
instructions for correct administration.
One of the influencing factors is the insuff icient, 
incomplete information in PILs. Recently we studied all 
PILs of INCS of different Dutch manufacturers. In total, 
31 PILs were analyzed and the complete instruction for 
administration of INCS consists of ten steps. Only in one 
PIL all ten steps for administration were described. Four of 
the ten steps included a missing instruction in some PILs. 
Three of the ten steps were described differently in some 
PILs.10 We conducted the same study in the UK, here 21 
PILs were analyzed and comparable results were gathered.11 
To achieve a uniform technique for the administration of 
INCS, complete and uniform instructions are needed in 
different PILs.
Either way, patients need to administer the medication 
optimally. This can be achieved by an additional instruc-
tion comparable with the existing instructions for adequate 
inhalation of lung medication.
Conclusion
In conclusion, this study shows that the technique used to 
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For this reason, more attention should be given to this in 
health care. Uniform and generally applicable instructions 
are needed and patients using INCS should be guided 
better.
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